Scientists investigate relapse after CAR t: blood draws hold clues

NCT ID NCT05397132

Completed Knowledge-focused Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tracks 50 people with blood cancers who are receiving CAR T therapy. Researchers will take blood samples over time to measure immune cells and genetic changes. The goal is to find patterns that predict or explain why the cancer comes back. This is an observational study, not a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors understand why some patients relapse after CAR T therapy, leading to better treatment strategies.
What could go wrong: This is an observational study, not a treatment trial. It may not directly improve outcomes, and results may take years to apply.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCY

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.